Share Name Share Symbol Market Type Share ISIN Share Description
Kromek LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 23.875p 23.75p 24.00p 23.875p 23.875p 23.875p 29,261.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.3 -4.1 -1.5 - 37.13

Kromek (KMK) Latest News

More Kromek News
Kromek Takeover Rumours

Kromek (KMK) Share Charts

1 Year Kromek Chart

1 Year Kromek Chart

1 Month Kromek Chart

1 Month Kromek Chart

Intraday Kromek Chart

Intraday Kromek Chart

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
20/11/201621:04Kromek Group PLC656.00
19/5/201507:23Kromek Group (KMK) - Overvalued AIM mugging177.00

Add a New Thread

Kromek (KMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

DateSubject
04/12/2016
08:20
Kromek Daily Update: Kromek is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 23.88p.
Kromek has a 4 week average price of 26.34p and a 12 week average price of 25.94p.
The 1 year high share price is 36p while the 1 year low share price is currently 23p.
There are currently 155,521,082 shares in issue and the average daily traded volume is 92,920 shares. The market capitalisation of Kromek is £37,130,658.33.
02/11/2016
17:55
daz: The announcement today further underpins the revenue forecast for this financial year. Any more contract announcements in the next few months and I think we will be seeing upgrades and the share price should follow.
04/7/2016
16:12
gnnmartin: It's always worrying when a share price sinks for no apparent reason. Last year's final results were announced on 30 July, along with a 'firm placing'. I can't help wondering if they are looking for more cash. I'll be happier (I hope) once we have the results.
23/6/2016
11:47
bapodra_investments: Can I ask why then it has not substantially increased the share price!
28/4/2016
19:15
bapodra_investments: I mean just look at the charts (above). It speaks volumes! There is more volume coming out of the charts than any buying or selling volume on this stock. Can anyone offer a seriously credible reason why the price action is not extremely positive on this stock? Can anyone offer a credible argument as to why this share price is not going upwards? Have a look at below which is from Proactive Investors today: ------------------------------------------------------------------------------------ Tech company investor Amphion Innovations Plc (LON:AMP) has drawn a further US$1.77mln from a loan facility secured against its holdings in Aim-listed Kromek (LON:KMK) and Motif Bio (LON: MTFB). Interest on the new funds will be a rate of 10% annually with repayments starting on 1 May and the final repayment due on 1 February. The facility was set up just under two years ago with a maximum draw down of US$10mln. The latest loan tranche will be used for working capital. It is secured on 7.77mln shares of Kromek and 14.9mln shares of Motif Bio. Richard Morgan, Amphion’s chief executive, said: "We continue to believe in the future upside potential of our holdings in both partner companies, Kromek and Motif Bio. “We are working on moving other programmes forward and this facility gives us access to additional working capital to progress the business' pipeline while these two partner companies develop further." Graham Lumsden, CEO of Motif Bio, said: "We welcome Amphion's continued commitment as a shareholder in Motif Bio." ------------------------------------------------------------------------------------ There is a big clue (above) for those savy investors who will realise what may be happening.
28/4/2016
14:49
bapodra_investments: Can anyone explain why the dire share price performance over the past several months then? This must have all been priced in and therefore Kromek became overpriced! It always worries me when a share price does not react to positive news in a proportionate manner.
23/3/2016
08:52
bapodra_investments: The DARPA deal has not made a difference to the share price. Now this concerns me. Bearing in mind that the stock market is a forward pricing mechanism looking say 6 months ahead then the fact the share price has not gone up tells me that revenue disability going forward is still a concern.
22/2/2016
09:26
philjeans: From Equity Development today; Kromek is pioneering digital colour imaging for x- and gamma rays, using cadmium zinc telluride crystals. Key markets include: medical imaging, homeland security and nuclear detection. 'Dirty bombs'are a terrifying prospect that, if detonated, would wreak havoc in large cities like New York. Not only causing death and destruction at the blast zone, but also widespread contamination of public areas potentially to be cordoned off for weeks or months. This is why the US Department and Defense (DoD), via its DARPA division (Defense Advanced Research Projects Agency), has just placed two landmark orders with Kromek worth $6.75m in total, to help safeguard the nation from such bombs. DARPA's long term vision is to establish a comprehensive security blanket across large swathes of the country - meaning that this contract could ultimately be expanded to cover literally 100ks (if not millions) of government employees under one huge integrated network. Better still, the $500/unit price point is a global first, and we understand active discussions are already in motion with at least 2-3 other major customers to deploy this patented technology. When this is added to the $7m of deals secured in H1, and January's $1m bone mineral densitometry contract, we estimate that total FY16 order intake will be >$15m - representing a book:bill ratio of at least 125%, based on turnover of £8.4m. Demand also shows that the adoption of truly disruptive technologies is likely to occur even in the face of macro-economic headwinds. Our estimates suggest that Kromek should become EBITDA and cashflow positive on annualised revenues of circa £11.5m and £14.5m. No changes are made to our 42p/share price target.
18/2/2016
19:58
bapodra_investments: Henderson raising their stake in Kromek to 5% yesterday is a encouraging sign. We need more fund management houses to take a stake in this company for the share price to really go up.
07/10/2015
16:55
archway1: I think there may well be a bid for the company , it stands to reason that now is the time to do it before the new revenues and profits kick in. I think this is going to go the exact same way as Xchanging . Top dog joins the board of company with depressed share price at its bottom. Outlook very strong and company now on firm financial footing. I smell a bidding war!!
05/10/2015
08:14
archway1: Kromek's X-ray success IP-backed small cap's future looks bright Extensively used by hospitals ,Durham University spin-out Kromek aims to take x-ray technology into new markets using its own patent protected Cadmium Zinc Telluride (CZT) crystal technology. This is s high risk play that will not suit every investor but we believe that for those willing to roll the dice there is substantial growth here. Consensus share price targets are pitched north of 43p implying nearly 60% upside. The time looks right given the depressed share price and what we believe could be a major boardroom appointment coup. The £43 m ill company has signed up Sir Peter Williams as its non-executive chairman, a man who has successfully walked the tightrope between academia and commercial markets for decades, including as a UK goverment adviser on science and education policy and as a former chief executive officer (CEO) of Oxford Instruments the world class science and research kit and tools maker. The appointment implies sound council at the helm of this emerging business, with the political and corporate clout to help the company speed along its commercial sales execution. Kromek is identifying medical, security screening , homeland security and nuclear radiation detection markets with colour imaging equipment that is affordable , easy to use and that gives instant results.
Kromek share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161205 00:34:31